Simvastatin does not affect CYP3A activity, quantified by the erythromycin breath test and oral midazolam pharmacokinetics, in healthy male subjects

Journal of Clinical Pharmacology

Volumn 40, Issue 11, 2000, Pages 1274-1279

  Prueksaritanont, Thomayant ^a   Vega, José M ^a   Rogers, J Douglas ^a   Gagliano, Kathleen ^a   Greenberg, Howard E ^b   Gillen, Lisa ^b   Brucker, Mary Jo ^a   McLoughlin, Debra ^a   Wong, Peggy H ^a   Waldman, Scott A ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CARBON 14; DRUG METABOLITE; ERYTHROMYCIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MIDAZOLAM; PLACEBO; SIMVASTATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BREATH ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG METABOLISM; HUMAN; HYPERCHOLESTEROLEMIA; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SPECTROMETER;

ADMINISTRATION, ORAL; ADULT; ARYL HYDROCARBON HYDROXYLASES; BREATH TESTS; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; ERYTHROMYCIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDAZOLAM; OXIDOREDUCTASES, N-DEMETHYLATING; SIMVASTATIN; SINGLE-BLIND METHOD;

EID: 0033735539     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/009127000004001112     Document Type: Article

References (18)

1. Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvastatin Survival Study
2. Metabolic disposition of simvastatin in patients with T-tube drainage
3. In vitro metabolism of simvastatin in humans: Identification of metabolizing enzymes and effect of the drug on hepatic P450s
4. Influence of age and gender on the plasma profiles of 3-hydroxy-3-methylglutaryl-coenzyme A (HMC-CoA) reductase inhibitory activity following multiple doses of lovastatin and simvastatin
5. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations
6. Inhibition and induction of cytochrome P450 and the clinical implications
7. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions
8. In vitro and in vivo drug interactions involving human CYP3A
9. Noninvasive tests of CYP3A enzymes
10. The erythromycin breath test selectively measures P450IIIA in patients with severe liver diseases
11. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: Lack of prediction by the erythromycin breath test
12. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A
13. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism
14. Differentiation of absorption and first pass gut and hepatic metabolism in humans: Studies with cyclosporine
15. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients
16. Regioselective biotransformation of midazolam by members of human cytochrome P4503A (CYP3A) subfamily
17. Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity
18. Midazolam: A review of its pharmacologic properties and therapeutic use